Lupin’s share price down today after US FDA issues adverse observations
By Ankur Chandra | Updated at: Sep 17, 2025 11:19 AM IST
Lupin’s share price is down today. This, after US FDA issued six adverse observations after the inspection of its Nagpur manufacturing unit. At 10:25 a.m. today, 17th September, 2025, its share price is down by 0.92%, trading at Rs 2,033. Nifty 50 index is up by 0.34% at this time.
US market very important for Lupin
Pharmaceutical companies that export their products to the US market have to comply with US Food & Drug Administration (FDA) regulations. US market is a very important one for Lupin. It currently accounts for around 39% of its total sales in value. The company has said that it will immediately take remedial measures at its Nagpur facility to address these adverse observations.
US is a very important market for generic drugs of Indian pharma companies. Indian pharma companies are already reeling under the 50% tariff that US government is currently imposing on Indian goods. Indian pharma companies have lost a large part of their comparative advantage because of these tariffs.
Lupin’s stock has underperformed in 2025
In the past 5 days, Lupin’s share has gained 2.20%. Year-to-date (YTD), in 2025, the share has lost 13.90%. YTD, the benchmark Nifty 50 index has gained 6.66%. So the stock has underperformed the benchmark Nifty 50 index by more than 7% this year.
Disclaimer : This content is only for informational purpose. It does not make any recommendation to act or invest.
Source: NSE
